Fig. 2.
CD19+/CD5+ cells in peripheral blood assessed by flow cytometry.
The ITT population included 93 patients. Clonal CD19+lymphocytosis in 89 patients was rapidly reduced with alemtuzumab therapy. Median number of malignant lymphocytes in the peripheral blood fell from 33.6 × 103/μL at baseline to 0.003 × 103/μL at week 4, and 0.001 × 103/μL at weeks 8 and 12.
